New data proves Tecfidera's effectiveness in MS, says Biogen

US biotech major Biogen (Nasdaq: BIIB) has presented new data which it sees as proof of the efficacy and safety of Tecfidera (dimethyl fumarate) in newly-diagnosed and previously treated patients with relapsing-remitting multiple sclerosis (RRMS).

The company is presenting real-world and clinical evidence on the product, which is currently approved in 24 countries including the USA, Canada, Australia and in the European Union, at this week’s Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

Ralph Kern, senior vice president, Worldwide Medical, Biogen, said: “As we continue to gather both clinical and real-world data, evidence shows that Tecfidera consistently demonstrates strong efficacy in reducing multiple sclerosis (MS) disease activity over the long term. The findings presented at ECTRIMS confirm the results we observed in the Tecfidera clinical trial program, further supporting its early use to improve outcomes for people living with MS.”